New Two-Year Data Confirm Genentech’s Vabysmo Improves Vision With Fewer Treatments for People With Wet-Age-Related Macular Degeneration

In the TENAYA and LUCERNE studies, more than 60% of Vabysmo patients could be treated every four months at two years. This represents an increase from 45% at year one
Patients treated with Vabysmo received a median number of 10 injections over the two years versus 15 injections for those treated with aflibercept, potentially decreasing the number of injections
No new safety signals were identified, and Vabysmo continued to be well tolerated, with a favorable benefit-risk profile

Excerpt from the Press Release:

South San Francisco, CA — July 14, 2022 —

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new two-year data from the TENAYA and LUCERNE studies that reinforce the long-term efficacy, safety and durability of Vabysmo^® (faricimab-svoa) in wet, or neovascular, age-related macular degeneration (AMD), a leading cause of vision loss. Wet AMD affects nearly 1.1 million people in the U.S. and can require treatment with eye injections every one to two months. The two-year data were presented at the 2022 American Society of Retina Specialists Annual Scientific Meeting on July 14. 

“These longer-term results reinforce confidence in Vabysmo and support its continued use in people with wet AMD,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “With the potential to require fewer injections over time, Vabysmo continues to represent an important step forward for people with vision-threatening retinal conditions, and these data exemplify our commitment to redefining standards of care and reducing treatment burden.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release